IRIDEX Corporation (IRIX)

Currency in USD
1.130
+0.010(+0.89%)
Closed·
IRIX Scorecard
Full Analysis
Quickly burning through cash
IRIX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.1201.188
52 wk Range
0.7822.140
Key Statistics
Prev. Close
1.12
Open
1.15
Day's Range
1.12-1.188
52 wk Range
0.782-2.14
Volume
35.32K
Average Volume (3m)
114.38K
1-Year Change
-40.21%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IRIX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

IRIDEX Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell

IRIDEX Corporation Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, it offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products that are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics through direct and independent sales force in the United States, as well as through independent distributors internationally. It operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

IRIDEX Corporation Earnings Call Summary for Q2/2025

  • IRIDEX beats Q2 2025 estimates: EPS of -$0.06 vs -$0.09 forecast, revenue of $13.6M vs $13.1M expected; stock up 3.17% post-announcement
  • Revenue grew 7% YoY, 14% sequentially; adjusted EBITDA improved to $21,000 from -$1.7M in 2024; operating expenses reduced by 28%
  • Gross profit margin declined to 34.5% from 40.7% in 2024; company faces challenges in Asian and Japanese markets
  • CEO aims for cash flow breakeven and positive adjusted EBITDA in 2025; focus on cost reduction and strategic growth initiatives
  • InvestingPro rates IRIX as undervalued with 'FAIR' Financial Health Score of 1.98; stock trades at P/B ratio of 25.62x
Last Updated: 12/08/2025, 22:44
Read Full Transcript

Compare IRIX to Peers and Sector

Metrics to compare
IRIX
Peers
Sector
Relationship
P/E Ratio
−3.5x−4.0x−0.5x
PEG Ratio
−0.07−0.200.00
Price/Book
325.4x2.5x2.6x
Price / LTM Sales
0.4x3.1x3.3x
Upside (Analyst Target)
-16.7%40.1%
Fair Value Upside
Unlock14.5%5.1%Unlock

Earnings

Latest Release
Aug 12, 2025
EPS / Forecast
-0.06 / -0.09
Revenue / Forecast
13.60M / 13.10M
EPS Revisions
Last 90 days

IRIX Income Statement

People Also Watch

5.56
REPL
+3.93%
70.44
ABVX
+1.27%
21.81
SRPT
+7.44%
5.3400
BGLC
-0.37%

FAQ

What Stock Exchange Does IRIDEX Trade On?

IRIDEX is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for IRIDEX?

The stock symbol for IRIDEX is "IRIX."

What Is the IRIDEX Market Cap?

As of today, IRIDEX market cap is 19.20M.

What Is IRIDEX's Earnings Per Share (TTM)?

The IRIDEX EPS (TTM) is -0.33.

When Is the Next IRIDEX Earnings Date?

IRIDEX will release its next earnings report on 17 Nov 2025.

From a Technical Analysis Perspective, Is IRIX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has IRIDEX Stock Split?

IRIDEX has split 0 times.

How Many Employees Does IRIDEX Have?

IRIDEX has 93 employees.

What is the current trading status of IRIDEX (IRIX)?

As of 17 Aug 2025, IRIDEX (IRIX) is trading at a price of 1.13, with a previous close of 1.12. The stock has fluctuated within a day range of 1.12 to 1.19, while its 52-week range spans from 0.78 to 2.14.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.